NCT02889822已完成1 期
The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Safety assessment of Alprostadil Liposome for Injection
研究概览
简要总结
Conducted in Chinese healthy adult volunteers,the study aims to observe the safety and tolerability of single/multiple-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range.
详细描述
Conducted in Chinese healthy adult volunteers,the study aims to observe the safety and tolerability of single/multiple-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range.
- Single dosing tolerability test in humans.There are 7 dose (10ug,20ug,50ug,100ug,200ug,300ug,400ug) groups in the single dosing tolerance test in healthy adult volunteers.The beginning dose of the study is 10ug,according to the dose escalation method,subjects who have successfully completed previous dose group and passed the safety assessment will enter the test of next dose group with the same method.
- Multiple dosing tolerability test in humans.Choose the proper dosage for multiple dosing tolerance test based on the single-dose tolerance test result.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers are at least 20 years of age and no older than
- •BMI are at least 19.0kg/m2,and no more than 24.0kg/m2.(The weight is greater than or equal to 50kg.)Subjects who are overweight or underweight will not be inclusion.
- •Subjects with normal heart rate( 60-100 beats per minute) as well as normal blood pressure(systolic blood pressure:90-120 mmHg;diastolic blood pressure:60-90 mmHg).
- •Subjects with normal medical history,vital signs,physical examination and clinical examination (routine blood,routine urine,blood chemistry,coagulation function and ECG,X-ray,intraocular pressure and so on).
- •A negative hepatitis B surface antigen,hepatitis C,HIV or syphilis test result.
- •Subjects with the ability to communicate with investigators.Besides,subjects must be willing to remain at the study center as required per protocal to complete all visit assessments.
- •Given their signed written informed consent to participate.
排除标准
- •Subjects have brain dysfunction,mental development disorders or speech disorders that unable to communicate with investigators.
- •Subjects with a history of psychiatric disease or drug dependence in the past 2 years.
- •Subjects with a medical history about cardiac,liver,renal,digestive system or neurological.
- •Subjects with the family history of diabetes,the history of pancreatitis,cholelithiasis or asthma.
- •Subjects significantly abuse alcohol or tobacco.
- •Drink in 24 hours before post-dosing of study drug.
- •Subjects who had taken medications within 2 weeks.
- •Subjects who had suffer from exsanguine or donated blood over 200ml will be excluded.
- •Subjects who participate in other clinical trials within 3 months will be excluded.
- •History of hypersensitivity or allergy to any of the study drugs or to drugs of similar chemical classes.
- •Subjects with a history of fainting.
- •Subjects who had infected for unknown reason.
- •Subjects with interstitial pneumonia.
- •Subjects with glaucoma or intraocular pressure with hyperthyroidism.
- •Women who were in the mentrual period.
- •Women who are pregnant or lactating.
研究组 & 干预措施
Alprostadil Liposomes for Injection
Experimental
- Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd
- Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days.
干预措施: Alprostadil Liposomes for Injection (Drug)
结局指标
主要结局
Safety assessment of Alprostadil Liposome for Injection
时间窗: 14 days
The safety assessment for this study include: 1. Adverse event（AEs） 2. Change from baseline in physical examination,vital signs,laboratory examinations 3. Local irritation symptoms
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluation of Liposomal Curcumin in Healthy VolunteersDrug SafetyNCT01403545SignPath Pharma, Inc.50
Unknown
1 期
The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult VolunteersLower Extremity Arterial Occlusive DiseasesNCT03669562CSPC ZhongQi Pharmaceutical Technology Co., Ltd.48
已完成
1 期
A Study of Lasmiditan in Healthy Chinese ParticipantsHealthyNCT04081324Eli Lilly and Company36
已完成
2 期
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung DiseaseMycobacterium Infections, NontuberculousMycobacteria, AtypicalNCT03038178Kevin Winthrop30
已完成
1 期
First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLLStrokeNCT05569720aptaTargets S.L.6